Evidence map›Paper›PMID 35238112›Full record

ArticleCancer science2022

Genomic analysis of familial pancreatic cancers and intraductal papillary mucinous neoplasms: A cross-sectional study.

Kodai Abe, Minoru Kitago, Kenjiro Kosaki, Mamiko Yamada, Eisuke Iwasaki, Shintaro Kawasaki, Keijiro Mizukami, Yukihide Momozawa, Chikashi Terao, Hiroshi Yagi and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Kodai AbeDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1138-7437
Minoru KitagoDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Kenjiro KosakiCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.
Mamiko YamadaCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.
Eisuke IwasakiDepartment of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shintaro KawasakiDepartment of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Keijiro MizukamiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Chikashi TeraoLaboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Hiroshi YagiDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yuta AbeDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yasushi HasegawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Shutaro HoriDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Masayuki TanakaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yutaka NakanoDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPRIKEN Center for Integrative Medical Sciences · JP

Funding

Kenko Kagaku Zaidan KenkoKagakuZaidan201902
6 · The paper itself

Abstract

Environmental and genetic factors play a critical role in the pathogenesis of pancreatic cancer, which is likely to follow a multistep process that includes intraductal papillary mucinous neoplasm. The pathogenesis of familial pancreatic cancer has been reported; however, epidemiological characteristics and causative genes remain unclear. This study aimed to determine the relationship between the family history of pancreatic cancer and tumor malignancy and identify novel susceptible germline variants of pancreatic cancer. We performed an epidemiologic study at our institute on a cohort of 668 patients with intraductal papillary mucinous neoplasm and 242 with pancreatic cancer but without associated intraductal papillary mucinous neoplasm stratified by family history of pancreatic cancer. Whole-exome sequencing was conducted for 10 patients from seven families with familial pancreatic cancer and intraductal papillary mucinous neoplasm. We found that patients who had intraductal papillary mucinous neoplasm with positive family history of pancreatic cancer within first-degree relatives were more likely to develop malignancy in a shorter period than those without family history. Duplicate frameshift variants in TET2 c.3180dupG (p.Pro1061fs) and ASXL1 c.1934dupG (p.Gly646fs) in one family and POLN c.1194dupT (p.Glu399fs) in another were identified as pathogenic truncating germline variants which were previously recognised susceptibility genes. Moreover, PDIA2 c.1403C>T (p.Pro468Leu) and DPYSL4 c.926C>A (p.Pro309Gln) were shared in four and two patients, respectively. In particular, PDIA2 was identified as a novel candidate for one of the deleterious variants of familial pancreatic cancer.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCarcinomaCross-Sectional StudiesGenomicsHumanscancer susceptibility genescross-sectional studyfamilial pancreatic cancergermline variantintraductal papillary mucinous neoplasm

Identifiers

PMID35238112
PMCPMC9128188
OpenAlexW4214847570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.